Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.

Respiratory medicine - 1 Nov 2019

Campo Paloma, Soto Campos Gregorio, Aparicio Marina Blanco, Jorge Ana Moreira, González Expósito Héctor Manuel, Quirce Santiago, Dávila Ignacio

Abstract excerpt

BACKGROUND: The appropriate identification of asthma phenotypes of responders to omalizumab would optimize the selection of treatment. OBJECTIVE: To describe the most frequent clinical phenotypes in patients with severe asthma responding to omalizumab and their clinical and pulmonary function improvement. METHODS: This was an observational, retrospective, multicenter study. Adult patients with severe asthma, who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Severity of Illness Index

Share to Treatment Outcome

Source

Identifiers

PMID: 31704593
DOI: 10.1016/j.rmed.2019.105804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.PMID 31704593Read ↗

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.Semantic proximity Read ↗

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

The efficacy of omalizumab treatment in patients with non-atopic severe asthmaSemantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.Semantic proximity Read ↗

Phenotypes and endotypes of uncontrolled severe asthma: new treatments.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patientsSemantic proximity Read ↗

Controversies and opportunities in severe asthma.Semantic proximity Read ↗

Severe refractory asthma: an update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.